QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

CompletedOBSERVATIONAL
Enrollment

679

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Type 2 Diabetes Mellitus
Trial Locations (34)

10588

Research Site, Goyang-si

12759

Research Site, Gwangju

13338

Research Site, Seongnam

13620

Research Site, Goyang-si

14220

Research Site, Gwangmyeong

16441

Research Site, Suwon

16825

Research Site, Gyeonggi-do

17049

Research Site, Yongin-si

17909

Research Site, Pyeongtaek-si

21550

Research Site, Incheon

22372

Research Site, Incheon

28325

Research Site, Cheongju-si

31931

Research Site, Seosan City

34944

Research Site, Daejeon

38885

Research Site, Yeongcheon-si

39550

Research Site, Gimcheon

44686

Research Site, Ulsan

47261

Research Site, Busan

48092

Research Site, Busan

49326

Research Site, Busan

51139

Research Site, Changwon-si

51495

Research Site, Changwon

52683

Research Site, Jinju

54807

Research Site, Jeonju

54999

Research Site, Jeonju

63241

Research Site, Jeju-do

02841

Research Site, Seoul

04763

Research Site, Seoul

05055

Research Site, Seoul

05372

Research Site, Seoul

07385

Research Site, Seoul

07441

Research Site, Seoul

07694

Research Site, Seoul

08832

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY